Medication Comparison · Updated November 2026

Ozempic vs Wegovy: Same Drug, Different Doses and Labels

Ozempic and Wegovy are both semaglutide, made by the same company (Novo Nordisk). But they are not identical. Wegovy goes to higher doses, has a weight management indication, carries cardiovascular outcome data in people without diabetes, and is now available as a daily pill. This comparison covers every practical difference that matters when you are choosing between them.

The Short Version

• Both are semaglutide by Novo Nordisk. Same active ingredient, same mechanism of action.
• Wegovy’s usual maintenance dose is 2.4 mg/week, with a 7.2 mg Wegovy HD option. Ozempic maxes out at 2 mg/week. See the Wegovy label and Ozempic label.
• Ozempic is FDA-approved for type 2 diabetes (2017). Wegovy is FDA-approved for weight management (2021). Many people use Ozempic off-label for weight loss.
• Self-pay prices are now similar. NovoCare lists Ozempic pens at $349/mo for 0.25 to 1 mg and $499 for 2 mg, and Wegovy pens at $349/mo (checked Nov 4, 2026). Ozempic is often easier to get through insurance if you have type 2 diabetes.
• Both now have pills. Wegovy tablets (1.5 to 25 mg daily) were added to the Wegovy label in December 2025. Ozempic tablets (1.5, 4 and 9 mg) are for type 2 diabetes only.
• Wegovy has SELECT cardiovascular data showing a 20% reduction in major cardiac events.

Quick Comparison Table

Active Ingredient: The Same Molecule

Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist. It works by mimicking the GLP-1 hormone your gut naturally produces after eating. Semaglutide slows gastric emptying (so food stays in your stomach longer), reduces appetite signals in the brain, and improves how your body handles insulin.

The molecule is identical in both drugs. Novo Nordisk manufactures both. Where they differ: the maximum dose, the FDA label, and (now) the available formulations.

The Dose Difference: Why It Matters

This is the most important clinical distinction between Ozempic and Wegovy.

Ozempic doses (weekly injection):

• 0.25 mg (starting, 4 weeks)
• 0.5 mg
• 1 mg
• 2 mg (max)

Wegovy doses (weekly injection):

• 0.25 mg (starting, 4 weeks)
• 0.5 mg
• 1 mg
• 1.7 mg
• 2.4 mg (usual maintenance)
• 7.2 mg (Wegovy HD, for people who tolerated 2.4 mg for at least 4 weeks and need more weight reduction)

The weight loss trials for semaglutide in people without diabetes used the 2.4 mg dose. STEP 1 showed 14.9% body weight loss at 68 weeks. Ozempic’s own trials were in people with type 2 diabetes and used 0.5 mg and 1 mg, with much smaller weight loss. There is no trial of Ozempic 2 mg for weight loss in people without diabetes, so we cannot say how close 2 mg comes to 2.4 mg.

Wegovy pill:

• Taken daily (not weekly)
• Starts at 1.5 mg and steps up every 30 days to a 25 mg maintenance dose
• In the OASIS 4 trial, oral semaglutide 25 mg produced 13.6% weight loss at 64 weeks vs 2.2% on placebo

The oral pill is a significant new option. See our full Wegovy pill vs injection comparison for details.

FDA Status and Off-Label Use

Ozempic has been FDA-approved for type 2 diabetes since 2017. Its label also covers heart and kidney risk reduction in adults with type 2 diabetes.

Wegovy was FDA-approved for chronic weight management on June 4, 2021, for adults with obesity or with overweight and at least one weight-related condition. It now also has heart risk reduction and MASH liver disease indications.

Here is the reality that most articles dance around: a large number of people take Ozempic off-label specifically for weight loss. Their doctors prescribe Ozempic instead of Wegovy because it is cheaper, better covered by insurance, and contains the same molecule. This is legal. Doctors can prescribe FDA-approved medications for off-label uses based on their clinical judgment.

The off-label route has trade-offs, though. Ozempic’s max dose is lower (2 mg vs 2.4 mg or 7.2 mg). It does not have weight management clinical data supporting its use for that purpose specifically. And insurance companies can (and sometimes do) deny coverage if the diagnosis code does not match the indication.

Weight Loss Data

Both drugs produce substantial weight loss. The data:

Wegovy (STEP 1 trial, 2.4 mg, 68 weeks):

• Average weight loss: 14.9%
• Half of participants (50.5%) lost 15% or more of body weight
• Placebo group: 2.4%

Semaglutide 2.4 mg vs liraglutide (STEP 8, 68 weeks):

• Semaglutide 2.4 mg (the Wegovy dose): 15.8%
• Daily liraglutide 3 mg: 6.4%

Ozempic in type 2 diabetes (SUSTAIN trials):

• SUSTAIN 1, 30 weeks: 3.73 kg (0.5 mg) and 4.53 kg (1 mg)
• SUSTAIN 2, 56 weeks: 4.3 kg (0.5 mg) and 6.1 kg (1 mg)

Head-to-head with tirzepatide (SURMOUNT-5, 72 weeks):

• Semaglutide (2.4 mg): 13.7% weight loss
• Tirzepatide (up to 15 mg): 20.2% weight loss

If you are comparing semaglutide to tirzepatide, tirzepatide wins on weight loss. Within the semaglutide family, the large weight loss numbers come from the 2.4 mg Wegovy dose in people without diabetes. Ozempic’s published results are from lower doses in people with diabetes, so they are not directly comparable.

For a full comparison across all GLP-1 medications, see our Mounjaro vs Ozempic vs Wegovy vs Zepbound page.

Cardiovascular Data: Wegovy’s Major Advantage

The SELECT trial is Wegovy’s strongest differentiator from Ozempic. This trial enrolled 17,604 adults with overweight or obesity and established cardiovascular disease who did not have diabetes. Participants received semaglutide 2.4 mg (the Wegovy dose) or placebo.

Results over a mean follow-up of 39.8 months: a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death).

This is not a weight loss finding. It is a cardiovascular outcome finding. The FDA updated Wegovy’s label to include a cardiovascular risk reduction indication based on SELECT.

Ozempic does not have equivalent cardiovascular outcome data for the weight management population. The SUSTAIN 6 trial showed cardiovascular benefits for Ozempic in people with type 2 diabetes, and Ozempic’s label includes a heart risk reduction indication for that group. That was at lower doses and in a different population.

If you have existing heart disease or significant cardiovascular risk factors, the SELECT data gives Wegovy a clear edge. Discuss this with your prescriber.

Side Effects

Same molecule, same side effects. The GI issues are the main concern:

• Nausea: Most common. Usually peaks in the first week or two at each new dose.
• Diarrhea and constipation: Opposite ends of the same spectrum. Some people get one, some get the other.
• Vomiting: Less common but possible, especially at higher doses.
• Decreased appetite: Expected. This is the drug working.
• Fatigue and headache: Reported in early weeks.

Rates on the Wegovy label (2.4 mg vs placebo):

• Nausea: 44% vs 16%
• Diarrhea: 30% vs 16%
• Vomiting: 24% vs 6%
• Constipation: 24% vs 11%

Most of these events were mild to moderate. In the Wegovy 2.4 mg trials, 6.8% of patients stopped treatment because of side effects, compared with 3.2% on placebo.

The step-up schedule exists to reduce GI side effects. Full breakdown in our GLP-1 side effects guide.

Cost Comparison

Prices from the Ozempic price guide and the Wegovy savings page, checked November 4, 2026. For people without insurance, the self-pay price is the same $349 for most doses, so cost no longer favors off-label Ozempic.

The more common scenario: your insurance covers Ozempic for diabetes but does not cover Wegovy for weight loss. In that case, a covered Ozempic copay will usually beat paying $349 a month for Wegovy. Without diabetes, though, Ozempic is off-label and many insurers check the diagnosis.

For a complete pricing comparison, see our cheapest GLP-1 online guide.

Insurance Coverage

Ozempic Coverage

Ozempic has been approved since 2017 for type 2 diabetes and is widely covered for that use. Prior authorization may be required.

For weight loss (off-label): Coverage varies. Some plans will cover Ozempic for a BMI-related diagnosis even without diabetes. Many will not. If you do not have diabetes, getting Ozempic covered is less predictable.

Wegovy Coverage

Wegovy was approved for weight management in 2021. Coverage has been expanding, particularly after the SELECT cardiovascular data was published. More commercial plans and some state Medicaid programs now include Wegovy.

The challenge: Many employer-sponsored plans still exclude anti-obesity medications. Medicare Part D excludes drugs used only for weight loss, though Wegovy’s heart indication can change that for some patients. Coverage is still far from universal.

The Off-Label Calculation

Here is the reality most people face: if you have type 2 diabetes, Ozempic is the easier insurance path. If you are using semaglutide for weight loss only, Wegovy is on-label but may not be covered. If you do not have type 2 diabetes, Wegovy is the on-label option. Prescribing Ozempic for weight loss alone is off-label, and many insurers check the diagnosis before they pay for it.

See our GLP-1 insurance coverage guide for tips on getting approved.

Choose Ozempic If…

• You have type 2 diabetes. Ozempic is on-label for T2D and is broadly covered by insurance. See how diabetes and weight-loss GLP-1 prescriptions differ.
• Your insurance covers it. With insurance and the savings card, copays can be as low as $25 a month.
• Your insurance covers Ozempic but not Wegovy. A covered Ozempic prescription beats an uncovered Wegovy prescription every time.
• Your prescriber is managing diabetes. Ozempic’s dose steps are set by blood sugar control, up to 2 mg.

Choose Wegovy If…

• You want the on-label weight loss indication. If your prescriber prefers on-label prescribing, Wegovy is the FDA-approved option for weight management.
• You have cardiovascular risk factors. The SELECT trial data (20% MACE reduction) gives Wegovy a meaningful clinical advantage for people with existing heart disease.
• You want the oral pill option. The Wegovy pill removes the injection requirement. See our pill vs injection comparison.
• You need a higher dose. If you have plateaued on Ozempic, Wegovy goes to 2.4 mg and, for some patients, 7.2 mg.
• Your insurance covers Wegovy. If coverage is not an issue, Wegovy is the more complete package: higher dose ceiling, CV data, and the pill option.

What About Compounded Semaglutide?

Compounded semaglutide is not FDA-approved, and its legal footing narrowed in 2025.

Compounded versions contain the same active ingredient but are not manufactured by Novo Nordisk. FDA declared the semaglutide shortage resolved on February 21, 2025, and the grace periods ended April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities. The quality, consistency, and regulatory status of compounded products differ from brand-name. We cover this in detail in our compounded vs brand-name GLP-1 guide.

With Wegovy self-pay at $349 a month, the savings from compounding are much smaller than they used to be. If you still go this route, ask which 503A pharmacy makes it and what legal pathway it relies on.

Frequently Asked Questions

Can I switch from Ozempic to Wegovy?

Yes, but the labels do not give a conversion between Ozempic and Wegovy doses, so your prescriber chooses the starting Wegovy dose. Do not switch or change doses on your own. The main reasons to switch are higher doses and on-label coverage for weight management.

Why do so many people use Ozempic for weight loss instead of Wegovy?

Mainly insurance. Ozempic has broader coverage because it is a diabetes drug, and semaglutide was on FDA’s shortage list until February 2025. Self-pay prices through NovoCare are now the same $349 for most doses, so cost alone is no longer a reason.

Is the Wegovy pill as effective as the injection?

Close, based on separate trials. Oral semaglutide 25 mg produced 13.6% weight loss at 64 weeks in OASIS 4, and the 2.4 mg injection produced 14.9% at 68 weeks in STEP 1. The pill is taken every morning on an empty stomach with up to 4 ounces of water, then you wait at least 30 minutes before eating, drinking or taking other oral medications. See our full Wegovy pill vs injection guide.

Does Medicare cover Ozempic or Wegovy?

Medicare Part D covers Ozempic for type 2 diabetes. Part D excludes drugs used only for weight loss, but some plans cover Wegovy for its heart risk reduction indication. Semaglutide also has a Medicare negotiated price that takes effect January 1, 2027. See our GLP-1 Medicare coverage guide for details.

Are there generics of Ozempic or Wegovy?

Compounded semaglutide is not a generic. It is a pharmacy-compounded version of the active ingredient, and it has not gone through the FDA approval process as a finished product. Check FDA’s Drugs@FDA database for any approved versions.

Last updated: November 2026. Pricing and availability may change. This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.

What we checked

This AI-assisted public-source desk check reviewed the Ozempic, Ozempic tablet and Wegovy prescribing information, FDA approval records and compounding policy, the STEP 1, STEP 8, SUSTAIN 1, SUSTAIN 2, SELECT, SURMOUNT-5 and OASIS 4 trial publications, NovoCare price pages and CMS’s negotiated price page on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.